fostamatinib
Solid results for AstraZeneca’s oral RA drug
September 23, 2010Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis
AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
